Kevin Moran's most recent trade in AlTi Global Inc - Ordinary Shares - Class A was a trade of 692,612 Restricted Stock Units done . Disclosure was reported to the exchange on June 27, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| AlTi Global Inc - Ordinary... | Kevin Moran | President and COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2025 | 692,612 | 692,612 | - | - | Restricted Stock Units | |
| AlTi Global Inc - Ordinary... | Kevin Moran | President and COO | Sale of securities on an exchange or to another person at price $ 3.47 per share. | 03 Jun 2025 | 28,509 | 60,311 | - | 3.5 | 98,927 | Class A Common Stock |
| AlTi Global Inc - Ordinary... | Kevin Moran | President and COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Mar 2025 | 106,464 | 106,464 | - | - | Restricted Stock Units | |
| Vanda Pharmaceuticals Inc | Kevin Moran | SVP, CFO & Treasurer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.76 per share. | 01 Mar 2025 | 26,941 | 328,822 (0%) | 0% | 4.8 | 128,239 | Common Stock |
| Vanda Pharmaceuticals Inc | Kevin Moran | SVP, CFO & Treasurer | Purchase of securities on an exchange or from another person at price $ 4.39 per share. | 21 Feb 2025 | 2,000 | 355,763 (0%) | 0% | 4.4 | 8,779 | Common Stock |
| Vanda Pharmaceuticals Inc | Kevin Moran | SVP, CFO & Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2025 | 125,000 | 353,763 (0%) | 0% | 0 | Common Stock | |
| AlTi Global Inc - Ordinary... | Kevin Moran | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 47,397 | 47,397 | - | - | Restricted Stock Units | |
| AlTi Global Inc - Ordinary... | Kevin Moran | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 47,397 | 75,034 | - | 0 | Class A Common Stock | |
| AlTi Global Inc - Ordinary... | Kevin Moran | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 13,785 | 27,570 | - | - | Restricted Stock Units | |
| AlTi Global Inc - Ordinary... | Kevin Moran | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 13,785 | 88,820 | - | 0 | Class A Common Stock | |
| AlTi Global Inc - Ordinary... | Kevin Moran | President and COO | Sale of securities on an exchange or to another person at price $ 4.00 per share. | 20 Aug 2024 | 137,500 | 27,637 | - | 4 | 550,000 | Class A Common Stock |
| Vanda Pharmaceuticals Inc | Kevin Moran | SVP, CFO & Treasurer | Sale of securities on an exchange or to another person at price $ 5.92 per share. | 29 Jul 2024 | 2,251 | 228,763 (0%) | 0% | 5.9 | 13,327 | Common Stock |
| AlTi Global Inc - Ordinary... | Kevin Moran | President and COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2024 | 236,967 | 236,967 | - | - | Peformance Restricted Stock Unit | |
| AlTi Global Inc - Ordinary... | Kevin Moran | President and COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2024 | 41,356 | 41,356 | - | - | Restricted Stock Units | |
| AlTi Global Inc - Ordinary... | Kevin Moran | See Remarks | Sale of securities on an exchange or to another person at price $ 4.70 per share. | 16 May 2024 | 10,047 | 165,137 | - | 4.7 | 47,221 | Class A Common Stock |
| AlTi Global Inc - Ordinary... | Kevin Moran | See Remarks | Sale of securities on an exchange or to another person at price $ 4.70 per share. | 14 May 2024 | 591 | 175,184 | - | 4.7 | 2,778 | Class A Common Stock |
| AlTi Global Inc - Ordinary... | Kevin Moran | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2024 | 150,000 | 195,775 | - | 0 | Class A Common Stock | |
| AlTi Global Inc - Ordinary... | Kevin Moran | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2024 | 150,000 | 695,759 | - | - | Class B Common Stock | |
| AlTi Global Inc - Ordinary... | Kevin Moran | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 4.93 per share. | 11 Mar 2024 | 20,000 | 175,775 | - | 4.9 | 98,600 | Class A Common Stock |
| Vanda Pharmaceuticals Inc | Kevin Moran | SVP, CFO & Treasurer | Sale of securities on an exchange or to another person at price $ 4.20 per share. | 04 Mar 2024 | 8,902 | 231,014 (0%) | 0% | 4.2 | 37,411 | Common Stock |
| Vanda Pharmaceuticals Inc | Kevin Moran | SVP, CFO & Treasurer | Sale of securities on an exchange or to another person at price $ 4.48 per share. | 04 Mar 2024 | 5,798 | 239,916 (0%) | 0% | 4.5 | 25,982 | Common Stock |
| Vanda Pharmaceuticals Inc | Kevin Moran | SVP, CFO & Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2024 | 125,000 | 245,714 (0%) | 0% | 0 | Common Stock | |
| AlTi Global Inc - Ordinary... | Kevin Moran | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2024 | 47,397 | 94,795 | - | - | Restricted Stock Units | |
| AlTi Global Inc - Ordinary... | Kevin Moran | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2024 | 47,397 | 68,819 | - | 0 | Class A Common Stock | |
| AlTi Global Inc - Ordinary... | Kevin Moran | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.65 per share. | 15 Feb 2024 | 23,044 | 45,775 | - | 5.7 | 130,201 | Class A Common Stock |
| Vanda Pharmaceuticals Inc | Kevin Moran | SVP, CFO & Treasurer | Sale of securities on an exchange or to another person at price $ 6.30 per share. | 28 Jul 2023 | 1,800 | 120,714 (0%) | 0% | 6.3 | 11,349 | Common Stock |
| Vanda Pharmaceuticals Inc | Kevin Moran | SVP, CFO & Treasurer | Sale of securities on an exchange or to another person at price $ 6.30 per share. | 28 Jul 2023 | 412 | 122,514 (0%) | 0% | 6.3 | 2,596 | Common Stock |
| Vanda Pharmaceuticals Inc | Kevin Moran | SVP, CFO & Treasurer | Sale of securities on an exchange or to another person at price $ 6.29 per share. | 15 Jun 2023 | 16,000 | 122,926 (0%) | 0% | 6.3 | 100,710 | Common Stock |
| AlTi Global Inc - Ordinary... | Kevin Moran | Chief Operating Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Jun 2023 | 85,691 | 0 | - | - | Warrant | |
| AlTi Global Inc - Ordinary... | Kevin Moran | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 21,422 | 21,422 | - | - | Class A Common Stock | |
| AlTi Global Inc - Ordinary... | Kevin Moran | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2023 | 142,193 | 142,193 | - | - | Restricted Stock Units | |
| Vanda Pharmaceuticals Inc | Kevin Moran | SVP, CFO & Treasurer | Sale of securities on an exchange or to another person at price $ 6.26 per share. | 02 Mar 2023 | 7,966 | 144,894 (0%) | 0% | 6.3 | 49,846 | Common Stock |
| Vanda Pharmaceuticals Inc | Kevin Moran | SVP, CFO & Treasurer | Sale of securities on an exchange or to another person at price $ 6.28 per share. | 02 Mar 2023 | 5,968 | 138,926 (0%) | 0% | 6.3 | 37,499 | Common Stock |
| Vanda Pharmaceuticals Inc | Kevin Moran | SVP, CFO & Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 77,500 | 77,500 | - | - | Stock Option (Right to Buy) | |
| Vanda Pharmaceuticals Inc | Kevin Moran | SVP, CFO & Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 32,700 | 152,860 (0%) | 0% | 0 | Common Stock | |
| Vanda Pharmaceuticals Inc | Kevin Moran | SVP, CFO & Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.12 per share. | 06 Dec 2022 | 7,500 | 124,952 (0%) | 0% | 3.1 | 23,400 | Common Stock |
| Vanda Pharmaceuticals Inc | Kevin Moran | SVP, CFO & Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Dec 2022 | 7,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Vanda Pharmaceuticals Inc | Kevin Moran | SVP, CFO & Treasurer | Sale of securities on an exchange or to another person at price $ 10.61 per share. | 06 Dec 2022 | 4,792 | 120,160 (0%) | 0% | 10.6 | 50,827 | Common Stock |
| Vanda Pharmaceuticals Inc | Kevin Moran | SVP, CFO & Treasurer | Sale of securities on an exchange or to another person at price $ 10.97 per share. | 28 Jul 2022 | 2,239 | 117,452 (0%) | 0% | 11.0 | 24,562 | Common Stock |
| Vanda Pharmaceuticals Inc | Kevin Moran | SVP, CFO & Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2022 | 77,500 | 77,500 | - | - | Stock Option (Right to Buy) | |
| Vanda Pharmaceuticals Inc | Kevin Moran | SVP, CFO & Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2022 | 32,700 | 131,996 (0%) | 0% | 0 | Common Stock | |
| Vanda Pharmaceuticals Inc | Kevin Moran | SVP, CFO & Treasurer | Sale of securities on an exchange or to another person at price $ 11.28 per share. | 28 Feb 2022 | 8,832 | 119,691 (0%) | 0% | 11.3 | 99,650 | Common Stock |
| Vanda Pharmaceuticals Inc | Kevin Moran | SVP, CFO & Treasurer | Sale of securities on an exchange or to another person at price $ 11.19 per share. | 28 Feb 2022 | 3,473 | 128,523 (0%) | 0% | 11.2 | 38,863 | Common Stock |
| Vanda Pharmaceuticals Inc | Kevin Moran | SVP, CFO & Treasurer | Sale of securities on an exchange or to another person at price $ 19.24 per share. | 28 Jul 2021 | 2,130 | 99,296 (0%) | 0% | 19.2 | 40,973 | Common Stock |
| Vanda Pharmaceuticals Inc | Kevin Moran | SVP, CFO & Treasurer | Sale of securities on an exchange or to another person at price $ 18.23 per share. | 01 Mar 2021 | 6,044 | 101,426 (0%) | 0% | 18.2 | 110,191 | Common Stock |
| Vanda Pharmaceuticals Inc | Kevin Moran | SVP, CFO & Treasurer | Sale of securities on an exchange or to another person at price $ 18.57 per share. | 01 Mar 2021 | 3,327 | 107,470 (0%) | 0% | 18.6 | 61,780 | Common Stock |
| Vanda Pharmaceuticals Inc | Kevin Moran | SVP, CFO & Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2021 | 77,500 | 77,500 | - | - | Employee Stock Option (Right to Buy) | |
| Vanda Pharmaceuticals Inc | Kevin Moran | SVP, CFO & Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2021 | 32,700 | 110,797 (0%) | 0% | - | Common Stock |